Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Colo. , July 31, 2014 ... awardee today with $25,000 to fund a translational ... inception in 2011, the gift was presented at ... Annual Meeting in Colorado Springs, ... specialize in neurointerventional approaches to neurovascular conditions, SNIS ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Electrodes for Medical Devices Market ... Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical ... Growth, Trends and Forecast, 2013 - 2019," the global ... 633.6 million in 2012 and is estimated to reach ...
(Date:7/31/2014)... DIEGO and SHENZHEN, China ... announced today the purchase of an Irys™System ... organization. BGI selected BioNano,s platform to enable comprehensive exploration ... improved assemblies for various organisms of interest, including those ... will partner together to develop new methods for multiplexing ...
(Date:7/31/2014)... IL (PRWEB) July 31, 2014 ... of automation across the U.S., increasing unemployment, depressing ... class. It is a Catch 22—we need ... but this means fewer jobs,” says economist and ... just-released Pollina Corporate Top 10 Pro-Business States for ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4
... ability to drive clients, success in managed care, ... Group, a,full-service managed market agency focused on securing ... of Dan Renick, RPh,as Managing Partner. Renick will ... biotech clients, including GlaxoSmithKline,sanofi-aventis, and Forest Laboratories., ...
... Abbott will present,at the Goldman Sachs Twenty-Ninth ... Thomas C. Freyman, executive vice president,finance and chief ... at 3:20 p.m. Central time., A live ... through,Abbott,s Investor Relations Web site at http://www.abbottinvestor.com ...
... China, May 28 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... focused on researching,developing, manufacturing and marketing biopharmaceutical ... Chief Operating Officer, and,Kevin Teo, Chief Financial ... Annual Global Healthcare Conference in Dana Point, ...
Cached Biology Technology:Dan Renick, RPh, Joins The Hobart Group as Managing Partner 2
(Date:7/31/2014)... prestin was found to be a key gene responsible for ... the hair cells of the inner ear that contracts and ... an antique phonograph horn, amplify sound waves to make hearing ... in the advanced online edition of Molecular Biology and ... has also independently evolved to play a critical role in ...
(Date:7/31/2014)... has long been known that biomass burning ... as a ritual , slash-and-burn agriculture and wildfires ... health. , But until the release of a ... Engineering Professor Mark Z. Jacobson, the degree of ... Jacobson,s research, detailed in a paper published July ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
... in dogs in western and central Africa comes from ... years ago, probably by European colonialists. In the current ... team of scientists from Africa, USA and France report ... at country level and that there is only limited ...
... supports a modest beneficial effect of anakinra for rheumatoid ... infections and its use with other biologic medications. ... many as one in 100 people worldwide. It affects ... one of a new breed of arthritis drugs licensed ...
... operations necessary to treat stroke victims, confront hardened arteries ... be made safer as researchers from the Micro/Nanophysics Research ... to the design of micro-motors small enough to be ... research paper, published today, Tuesday, 20 January, in IOP ...
Cached Biology News:Hope for a rabies eradication strategy in Africa 2Anakinra for rheumatoid arthritis: A modest benefit with some risk 2Microbot motors fit to swim human arteries 2
Hamster serum...
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
Canine Serum...
CASPR (H-66)...
Biology Products: